Mehrdad Payandeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mehrdad Payandeh has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Masoud Sadeghi
Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
24 shared publications - Edris Sadeghi
Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
22 shared publications Edris Sadeghi
5 shared publicationsSeyed-Hamid Madani
5 shared publications- Atefeh Nasir Kansestani
Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China
4 shared publications - Mohammad Erfan Zare
Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China
4 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Brieflands in Journal of Kermanshah University of Medical Sciences
- Vol. 30 (2) , e171332
Possible Recurrence of Synovial Sarcoma Involving the Shoulder of a 57-Year-Old Female: A Rare Case Report from Iran
Introduction: Synovial sarcoma (SS) is an uncommon malignant soft-tissue tumor that typically presents as a slow-growing mass in the extremities, adjacent to joint capsules. SS has three subtypes: monophasic, biphasic, and poorly differentiated. Standard treatment primarily involves complete surgical resection of the tumor mass, with or without adjuvant or neoadjuvant therapies. Case Presentation: We report a possible recurrence of SS in the left shoulder of a 57-year-old woman 2 decades after the initial diagnosis. She had previously undergone surgical resection of SS in the right axilla. Years later, a tumor developed in the contralateral shoulder, with regional lymph-node involvement. Magnetic resonance imaging and computed tomography revealed a large infiltrative mass with internal vasculature and bone involvement in the left shoulder. Pathological analysis supported the diagnosis of monophasic SS based on cellular morphology and the expression profile of markers including CD99, epithelial membrane antigen, and Bcl-2. The patient declined surgical resection and received 8 cycles of chemotherapy with doxorubicin and ifosfamide. She died of cardiorespiratory arrest 18 months after the diagnosis of the recurrent tumor. Conclusions: SS is characterized by a high rate of metastasis and may recur more than 5 years after initial diagnosis. This case underscores the need for long-term surveillance and careful evaluation of new soft-tissue masses in patients with a history of SS.
- 30 June 2026
- Published by Brieflands in Journal of Kermanshah University of Medical Sciences
- Vol. 30 (2) , e171332
Open AccessPossible Recurrence of Synovial Sarcoma Involving the Shoulder of a 57-Year-Old Female: A Rare Case Report from Iran
Introduction: Synovial sarcoma (SS) is an uncommon malignant soft-tissue tumor that typically presents as a slow-growing mass in the extremities, adjacent to joint capsules. SS has three subtypes: monophasic, biphasic, and poorly differentiated. Standard treatment primarily involves complete surgical resection of the tumor mass, with or without adjuvant or neoadjuvant therapies. Case Presentation: We report a possible recurrence of SS in the left shoulder of a 57-year-old woman 2 decades after the initial diagnosis. She had previously undergone surgical resection of SS in the right axilla. Years later, a tumor developed in the contralateral shoulder, with regional lymph-node involvement. Magnetic resonance imaging and computed tomography revealed a large infiltrative mass with internal vasculature and bone involvement in the left shoulder. Pathological analysis supported the diagnosis of monophasic SS based on cellular morphology and the expression profile of markers including CD99, epithelial membrane antigen, and Bcl-2. The patient declined surgical resection and received 8 cycles of chemotherapy with doxorubicin and ifosfamide. She died of cardiorespiratory arrest 18 months after the diagnosis of the recurrent tumor. Conclusions: SS is characterized by a high rate of metastasis and may recur more than 5 years after initial diagnosis. This case underscores the need for long-term surveillance and careful evaluation of new soft-tissue masses in patients with a history of SS.
- Open Access
- 1 January 2026
- Published by Wiley in Advances in Hematology
- Vol. 2026 (1)
Genetic Analysis of Imatinib Resistance in CML: The Role of T315I and E255K
Background and Aims: Imatinib mesylate is a small molecule inhibitor targeting the BCR‐ABL tyrosine kinase. However, some CML patients develop resistance to imatinib. This resistance is commonly associated with mutations in the kinase domain of BCR‐ABL, notably the prevalent T315I and E255K mutations. We evaluated the frequency of E255K and T315I mutations in CML patients who do not respond to imatinib therapy. Methods: Twenty imatinib‐resistant CML patients were selected from a total cohort of 100 CML patients undergoing regular follow‐up. Genomic screening for the T315I and E255K mutations was carried out using a two‐step molecular approach: initial reverse transcription‐PCR (RT‐PCR) amplification of the ABL kinase domain, followed by restriction fragment length polymorphism (RFLP) analysis. The subsequent clinical management and outcomes for patients harboring these mutations were meticulously tracked and analyzed. Results: The T315I and E255K mutations were present in 20% (4/20) and 10% (2/20) of the imatinib‐resistant patients, respectively. All patients required an immediate switch to second‐line tyrosine kinase inhibitors. Notably, one patient with the T315I mutation secured ponatinib and achieved remission, while three other patients underwent allogeneic stem cell transplantation. Two patients carrying the E255K mutation ultimately progressed to blast crisis and died, highlighting the particularly dire prognosis associated with this mutation. Conclusion: The T315I and E255K mutations are significant contributors to imatinib resistance in our patient population and are linked to an aggressive clinical course. These findings underscore the critical importance of integrating routine mutation screening into clinical practice to enable early treatment modification, facilitate access to advanced therapies, and ultimately improve patient outcomes.
- 1 January 2026
- Published by Wiley in Advances in Hematology
- Vol. 2026 (1)
Open AccessGenetic Analysis of Imatinib Resistance in CML: The Role of T315I and E255K
Background and Aims: Imatinib mesylate is a small molecule inhibitor targeting the BCR‐ABL tyrosine kinase. However, some CML patients develop resistance to imatinib. This resistance is commonly associated with mutations in the kinase domain of BCR‐ABL, notably the prevalent T315I and E255K mutations. We evaluated the frequency of E255K and T315I mutations in CML patients who do not respond to imatinib therapy. Methods: Twenty imatinib‐resistant CML patients were selected from a total cohort of 100 CML patients undergoing regular follow‐up. Genomic screening for the T315I and E255K mutations was carried out using a two‐step molecular approach: initial reverse transcription‐PCR (RT‐PCR) amplification of the ABL kinase domain, followed by restriction fragment length polymorphism (RFLP) analysis. The subsequent clinical management and outcomes for patients harboring these mutations were meticulously tracked and analyzed. Results: The T315I and E255K mutations were present in 20% (4/20) and 10% (2/20) of the imatinib‐resistant patients, respectively. All patients required an immediate switch to second‐line tyrosine kinase inhibitors. Notably, one patient with the T315I mutation secured ponatinib and achieved remission, while three other patients underwent allogeneic stem cell transplantation. Two patients carrying the E255K mutation ultimately progressed to blast crisis and died, highlighting the particularly dire prognosis associated with this mutation. Conclusion: The T315I and E255K mutations are significant contributors to imatinib resistance in our patient population and are linked to an aggressive clinical course. These findings underscore the critical importance of integrating routine mutation screening into clinical practice to enable early treatment modification, facilitate access to advanced therapies, and ultimately improve patient outcomes.
- 1 January 2026
- Published by Duncker & Humblot GmbH in Die Verwaltung
- Vol. 59 (1) , 49-86
Personale Fördermaßnahmen in der Verwaltung der postmigrantischen Gesellschaft
Ein Forum für die Wissenschaft seit 1798.
- 1 January 2026
- Published by Duncker & Humblot GmbH in Die Verwaltung
- Vol. 59 (1) , 49-86
Personale Fördermaßnahmen in der Verwaltung der postmigrantischen Gesellschaft
Ein Forum für die Wissenschaft seit 1798.
- Open Access
- 14 December 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (12)
An Umbrella Review of Meta‐Analyses on the Efficacy and Safety of Eltrombopag in Immune Thrombocytopenia
Background and Aims: Immune thrombocytopenia (ITP) is an autoimmune disorder with increased bleeding risk. Eltrombopag, an oral thrombopoietin receptor agonist, is widely used after corticosteroids or immunoglobulins. Multiple meta‐analyses support its efficacy, yet safety concerns persist. We conducted an umbrella review to synthesize evidence on efficacy and safety across age groups. Methods: We searched PubMed, Scopus, and Web of Science through April 2025 for systematic reviews/meta‐analyses on eltrombopag in ITP. Methodological quality was appraised using AMSTAR 2. Outcomes included platelet response, bleeding, and adverse events. We mapped primary trials across reviews to address overlap and qualitatively summarized findings; no new pooling was performed. Results: Nine meta‐analyses met inclusion. Across adult/mixed populations, eltrombopag increased platelet response (e.g., RR ≈ 3.4, p < 0.001) and reduced bleeding; pediatric effects were directionally similar but less precise with higher heterogeneity. Reported adverse events included hepatobiliary abnormalities and thrombotic events, underscoring the need for monitoring. Conclusion: Eltrombopag is effective in raising platelet counts and reducing bleeding in ITP. Benefits appear to increase up to ~50 mg daily and plateau thereafter. Age‐related variability and safety considerations support individualized dosing and vigilant follow‐up.
- 14 December 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (12)
Open AccessAn Umbrella Review of Meta‐Analyses on the Efficacy and Safety of Eltrombopag in Immune Thrombocytopenia
Background and Aims: Immune thrombocytopenia (ITP) is an autoimmune disorder with increased bleeding risk. Eltrombopag, an oral thrombopoietin receptor agonist, is widely used after corticosteroids or immunoglobulins. Multiple meta‐analyses support its efficacy, yet safety concerns persist. We conducted an umbrella review to synthesize evidence on efficacy and safety across age groups. Methods: We searched PubMed, Scopus, and Web of Science through April 2025 for systematic reviews/meta‐analyses on eltrombopag in ITP. Methodological quality was appraised using AMSTAR 2. Outcomes included platelet response, bleeding, and adverse events. We mapped primary trials across reviews to address overlap and qualitatively summarized findings; no new pooling was performed. Results: Nine meta‐analyses met inclusion. Across adult/mixed populations, eltrombopag increased platelet response (e.g., RR ≈ 3.4, p < 0.001) and reduced bleeding; pediatric effects were directionally similar but less precise with higher heterogeneity. Reported adverse events included hepatobiliary abnormalities and thrombotic events, underscoring the need for monitoring. Conclusion: Eltrombopag is effective in raising platelet counts and reducing bleeding in ITP. Benefits appear to increase up to ~50 mg daily and plateau thereafter. Age‐related variability and safety considerations support individualized dosing and vigilant follow‐up.
- Open Access
- 1 August 2025
- Published by Croatian Medical Journals in Croatian Medical Journal
- Vol. 66 (4) , 299-304
Multimodal treatment approach with sunitinib, pembrolizumab, bevacizumab, sirolimus, and zoledronic acid for locally advanced clear cell renal cell carcinoma: a case report
Locally advanced renal cell carcinoma (RCC) presents significant therapeutic challenges, particularly in resource-limited settings with restricted access to new therapies. This report describes a new exploratory multimodal therapeutic approach for a ...
- 1 August 2025
- Published by Croatian Medical Journals in Croatian Medical Journal
- Vol. 66 (4) , 299-304
Open AccessMultimodal treatment approach with sunitinib, pembrolizumab, bevacizumab, sirolimus, and zoledronic acid for locally advanced clear cell renal cell carcinoma: a case report
Locally advanced renal cell carcinoma (RCC) presents significant therapeutic challenges, particularly in resource-limited settings with restricted access to new therapies. This report describes a new exploratory multimodal therapeutic approach for a ...
- Open Access
- 23 October 2024
- Published by Knowledge E DMCC in Iranian Journal of Microbiology
- Vol. 16 (5) , 648-654
Gut microbiota and graft-versus-host disease in hematopoietic stem cell transplant patients
Background and Objectives: Graft-versus-host disease (GvHD) frequently complicates hematopoietic stem cell transplan- tation (HSCT). Emerging evidence suggests a correlation between gut microbiota and GvHD risk. This study aims to eluci- date the microbiota profiles in HSCT patients before and after transplantation and their association with GvHD. Materials and Methods: This study, conducted from December 2022 to December 2023, involved the collection of 15 stool samples from HSCT patients. Bacterial content was quantified using real-time PCR, while interleukin-6 levels were assessed via ELISA. Results: Among the 15 participants (8 male, 7 female), 9 underwent allogeneic HSCT (allo-HSCT) and 6 received autol- ogous HSCT. In the aGvHD group, there was a significant reduction in the abundance of Bacteroides and Bifidobacterium compared to those without aGvHD. Additionally, declines were observed in Clostridium and Firmicutes populations. The genus Blautia also showed reduced prevalence in the aGvHD group, whereas no significant differences were noted in the uncomplicated group. ELISA analysis revealed that interleukin-6 levels remained within the normal range (30-960 pg/ml) with no significant elevation in the aGvHD group. Conclusion: The study highlights a notable association between alterations in gut microbiota, specifically reductions in certain bacterial populations and the development of aGvHD following allo-HSCT.
- 23 October 2024
- Published by Knowledge E DMCC in Iranian Journal of Microbiology
- Vol. 16 (5) , 648-654
Open AccessGut microbiota and graft-versus-host disease in hematopoietic stem cell transplant patients
Background and Objectives: Graft-versus-host disease (GvHD) frequently complicates hematopoietic stem cell transplan- tation (HSCT). Emerging evidence suggests a correlation between gut microbiota and GvHD risk. This study aims to eluci- date the microbiota profiles in HSCT patients before and after transplantation and their association with GvHD. Materials and Methods: This study, conducted from December 2022 to December 2023, involved the collection of 15 stool samples from HSCT patients. Bacterial content was quantified using real-time PCR, while interleukin-6 levels were assessed via ELISA. Results: Among the 15 participants (8 male, 7 female), 9 underwent allogeneic HSCT (allo-HSCT) and 6 received autol- ogous HSCT. In the aGvHD group, there was a significant reduction in the abundance of Bacteroides and Bifidobacterium compared to those without aGvHD. Additionally, declines were observed in Clostridium and Firmicutes populations. The genus Blautia also showed reduced prevalence in the aGvHD group, whereas no significant differences were noted in the uncomplicated group. ELISA analysis revealed that interleukin-6 levels remained within the normal range (30-960 pg/ml) with no significant elevation in the aGvHD group. Conclusion: The study highlights a notable association between alterations in gut microbiota, specifically reductions in certain bacterial populations and the development of aGvHD following allo-HSCT.
- Open Access
- 1 January 2023
- Published by Verlag C.H.Beck GmbH & Co. KG in Zeitschrift für ausländisches öffentliches Recht und Völkerrecht / Heidelberg Journal of International Law
- Vol. 83 (4) , 609-628
Verfassungsrechtliche Grundlagen der Völkerrechtsfreundlichkeit in Deutschland
The provisions of the Basic Law with references to international law form the foundation of the constitutional principle of friendliness towards internati…
- 1 January 2023
- Published by Verlag C.H.Beck GmbH & Co. KG in Zeitschrift für ausländisches öffentliches Recht und Völkerrecht / Heidelberg Journal of International Law
- Vol. 83 (4) , 609-628
Open AccessVerfassungsrechtliche Grundlagen der Völkerrechtsfreundlichkeit in Deutschland
The provisions of the Basic Law with references to international law form the foundation of the constitutional principle of friendliness towards internati…
- 27 November 2022
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 21 (1) , 1-7
Examining the Psychometric Properties of the Farsi Version of the Body Image Scale for Breast Cancer Survivors
Background Mastectomy as a surgical treatment in women with breast cancer causes a change in their body image due to the loss of femininity and body integrity, decreased sense of sexual attractiveness, and dissatisfaction with the presence of surgical scars. The present study was conducted to evaluate the psychometric properties of the Farsi version of the body image scale for breast cancer survivors. Methods This cross-sectional study was conducted on 204 women with a mastectomy referred to Kermanshah's surgery and oncology office in 2021. Face and content validity were evaluated qualitatively. Construct validity was evaluated by exploratory factor analysis (with maximum likelihood and Promax rotation) and confirmatory factor analysis. Cronbach’s alpha and McDonald’s omega coefficients were used to verify internal consistency. Results The mean age of the participants was 46.57 (SD = 9.47). One factor was extracted that explained 46.56% of the total variance of body image. The factor load of the items varied between 0.561 and 0.801. The results of CFA also showed that the final model has a perfect fit: CMIN = 20.931; DF = 13; CMIN/FD = 1.610; p = 0.074; GFI = 0.972; AGFI = 0.939; IFI = 0.985; CFI = 0.985; TLI = 0.975; PNFI = 0.595; PCFI = 0.610; RMSEA = 0.055. internal consistency based on Cronbach's alpha and McDonald's omega coefficients was 0.856 and 0.861, respectively. Conclusion The Farsi version of the body image scale for breast cancer survivors has good construct validity and may be used in various studies in clinical and research settings.
- 27 November 2022
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 21 (1) , 1-7
Examining the Psychometric Properties of the Farsi Version of the Body Image Scale for Breast Cancer Survivors
Background Mastectomy as a surgical treatment in women with breast cancer causes a change in their body image due to the loss of femininity and body integrity, decreased sense of sexual attractiveness, and dissatisfaction with the presence of surgical scars. The present study was conducted to evaluate the psychometric properties of the Farsi version of the body image scale for breast cancer survivors. Methods This cross-sectional study was conducted on 204 women with a mastectomy referred to Kermanshah's surgery and oncology office in 2021. Face and content validity were evaluated qualitatively. Construct validity was evaluated by exploratory factor analysis (with maximum likelihood and Promax rotation) and confirmatory factor analysis. Cronbach’s alpha and McDonald’s omega coefficients were used to verify internal consistency. Results The mean age of the participants was 46.57 (SD = 9.47). One factor was extracted that explained 46.56% of the total variance of body image. The factor load of the items varied between 0.561 and 0.801. The results of CFA also showed that the final model has a perfect fit: CMIN = 20.931; DF = 13; CMIN/FD = 1.610; p = 0.074; GFI = 0.972; AGFI = 0.939; IFI = 0.985; CFI = 0.985; TLI = 0.975; PNFI = 0.595; PCFI = 0.610; RMSEA = 0.055. internal consistency based on Cronbach's alpha and McDonald's omega coefficients was 0.856 and 0.861, respectively. Conclusion The Farsi version of the body image scale for breast cancer survivors has good construct validity and may be used in various studies in clinical and research settings.
- Open Access
- 6 December 2021
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (2) , 588-592
Human placental mesenchymal stromal cell‐derived exosome‐enriched extracellular vesicles for chronic cutaneous graft‐versus‐host disease: A case report
- 6 December 2021
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (2) , 588-592
Open AccessHuman placental mesenchymal stromal cell‐derived exosome‐enriched extracellular vesicles for chronic cutaneous graft‐versus‐host disease: A case report
- Open Access
- 14 January 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-11
Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins
Breast cancer is currently the most common neoplasm diagnosed in women globally. There is a growing body of evidence to suggest that human papillomavirus (HPV) infection may play a key role in invasiveness of breast cancer. The aim of this study was to determine the presence of HPV in patients with breast cancer and its possible association with cancer progression. Breast specimens were collected from 72 patients with breast cancer and 31 healthy controls. The presence of HPV was investigated by polymerase chain reaction (PCR) and genotyping was performed for positive cases. We also evaluated the viral factors such as E6, E2, and E7 in HPV positive cases. Enzyme-linked immunosorbent assay (ELISA (and Real-time PCR techniques were used to measure the expression level of anti-carcinogenic genes, such as p53, retinoblastoma (RB), breast and ovarian cancer susceptibility gene (BRCA1, BRCA2) and inflammatory cytokines, including tumor necrosis factor α (TNF-α), transforming growth factor β (TGF-β), nuclear factor-kB (NF-kB), and different interleukins [ILs] (IL-1,IL6, and IL-17). The HPV DNA was detected in 48.6% of breast cancer samples, whereas only 16.1% of controls were positive for HPV. We observed statistically significant differences between breast cancer patients and HPV presence (P = 0.003). HPV type 18 was the most prevalent virus genotype in patients. The expression of P53, RB, BRCA1, and BRCA2 were decreased in patients with HPV-positive breast cancer as compared to HPV-negative breast cancer and healthy controls. (All P-values were less than 0.05). The presence of the HPV was associated with increased inflammatory cytokines (IL-1, IL-6, IL-17, TGF-β, TNF-α, and NF-kB) and tumor progression. The present study demonstrated that HPV infection may implicate in the development of some types of breast cancer.
- 14 January 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-11
Open AccessHuman papilloma virus and breast cancer: the role of inflammation and viral expressed proteins
Breast cancer is currently the most common neoplasm diagnosed in women globally. There is a growing body of evidence to suggest that human papillomavirus (HPV) infection may play a key role in invasiveness of breast cancer. The aim of this study was to determine the presence of HPV in patients with breast cancer and its possible association with cancer progression. Breast specimens were collected from 72 patients with breast cancer and 31 healthy controls. The presence of HPV was investigated by polymerase chain reaction (PCR) and genotyping was performed for positive cases. We also evaluated the viral factors such as E6, E2, and E7 in HPV positive cases. Enzyme-linked immunosorbent assay (ELISA (and Real-time PCR techniques were used to measure the expression level of anti-carcinogenic genes, such as p53, retinoblastoma (RB), breast and ovarian cancer susceptibility gene (BRCA1, BRCA2) and inflammatory cytokines, including tumor necrosis factor α (TNF-α), transforming growth factor β (TGF-β), nuclear factor-kB (NF-kB), and different interleukins [ILs] (IL-1,IL6, and IL-17). The HPV DNA was detected in 48.6% of breast cancer samples, whereas only 16.1% of controls were positive for HPV. We observed statistically significant differences between breast cancer patients and HPV presence (P = 0.003). HPV type 18 was the most prevalent virus genotype in patients. The expression of P53, RB, BRCA1, and BRCA2 were decreased in patients with HPV-positive breast cancer as compared to HPV-negative breast cancer and healthy controls. (All P-values were less than 0.05). The presence of the HPV was associated with increased inflammatory cytokines (IL-1, IL-6, IL-17, TGF-β, TNF-α, and NF-kB) and tumor progression. The present study demonstrated that HPV infection may implicate in the development of some types of breast cancer.